Providing unmatched treatments that address all forms of bleeding
Bleeding is a critical health problem for the entire world. Patients who are on antiplatelet drugs such as Plavix are especially prone to bleeding, with few options for treatment. This market potential exceeds $10B annually in the US. CAY001 - our lead candidate - is a systemic drug designed to target bleeding in patients on antiplatelet drugs to reduce blood loss and save lives.
Cayuga Biotech is a startup company developing novel hemostatic drugs and devices to treat uncontrollable bleeding episodes. CAY001’s mechanism of action potentially gives it a better safety profile than current drugs on the market, a key competitive advantage. Following success in antiplatelet indications, we plan to expand usage to all bleeding scenarios.
- Cayuga Biotech Promo Video and Q&A | IndieBio | SOSV - The Accelerator VC
- Founder Story: Cayuga - Can a drug promote healthy clotting to make extreme bleeding treatable?
- Cayuga Hero Shot
You might also be interested in
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.